2022 ASCO Annual Assembly Analysis Spherical Up: Advances in Treating A couple of Myeloma, Breast Most cancers, and Most cancers in Other folks 60 and Older

In the yearly Analysis Spherical Up collection, participants of the American Society of Scientific Oncology (ASCO) solution the query, “What used to be essentially the most thrilling or practice-changing analysis on your box introduced on the 2022 ASCO Annual Assembly?” On this episode, 3 mavens talk about new analysis from the assembly on more than one myeloma, breast most cancers, and most cancers in other folks age 60 or older.

Concentrate underneath, and subscribe to Most cancers.Web Podcasts anyplace you pay attention to podcasts for brand new episodes on this collection.

New analysis in treating more than one myeloma

Dr. Sagar Lonial, the 2022 Most cancers.Web Affiliate Editor for Myeloma, discusses the section 3 DETERMINATION scientific trial, which used to be learning whether or not together with an autologous bone marrow/stem mobile transplant early within the remedy plan for more youthful other folks with newly recognized more than one myeloma not on time most cancers enlargement or unfold. [1:44]

Advances in treating breast most cancers

Dr. Norah Lynn Henry

Dr. Norah Lynn Henry, the 2022 Most cancers.Web Affiliate Editor for Breast Most cancers, breaks down 4 research in breast most cancers. First, she discusses 2 research in complicated breast most cancers. The primary find out about, which used to be the section 3 DESTINY-04 scientific trial, used to be comparing whether or not the focused treatment drug trastuzumab deruxtecan (Enhertu) may lengthen most cancers enlargement or unfold in other folks with metastatic HER2-low breast most cancers and lend a hand them are living longer. [9:13] Subsequent, Dr. Henry discusses the section 3 TROPiCS-02 scientific trial, which used to be learning whether or not the focused treatment drug sacituzumab govitecan (Trodelvy) not on time most cancers enlargement for longer than usual chemotherapy in other folks with complicated hormone receptor-positive, HER2-negative breast most cancers whose most cancers had grown regardless of earlier therapies. [11:05]

Dr. Henry then discusses 2 research in early-stage breast most cancers, beginning with the section 3 LUMINA scientific trial. This find out about used to be comparing whether or not some other folks with low-grade luminal A breast most cancers may steer clear of radiation treatment after surgical procedure with out it impacting their possibility of recurrence. [12:40] In the end, Dr. Henry supplies an replace from the section 3 ABCSG-18 scientific trial, which used to be learning whether or not the bone enhancing drug denosumab (Prolia, Xgeva) may lend a hand postmenopausal other folks with early-stage, hormone receptor-positive breast most cancers who have been receiving aromatase inhibitor treatment steer clear of bone fracture and recurrence. [14:14]

Growth in treating other folks age 60 or older with most cancers

Dr. Shakira Grant

Dr. Shakira Grant, an assistant professor in hematology on the College of North Carolina at Chapel Hill who makes a speciality of the care of older adults, discusses 3 research within the remedy of other folks age 60 or older with most cancers. First, she discusses the consequences from a registry find out about exploring whether or not residing in a rural space higher impairment, similar to diminished bodily serve as and high quality of existence, amongst other folks age 60 or older with most cancers and impacted their total survival. [17:24] Subsequent, Dr. Grant discusses a find out about the use of a frailty size in keeping with data in sufferers’ digital well being information to acquire insights about how the frailty stage of other folks with most cancers over the age of 65 can impact their total survival. [21:15] In the end, Dr. Grant discusses the section 3 ASTER 70s scientific trial, which used to be learning whether or not sufferers older than 70 with estrogen receptor-positive, HER2-negative breast most cancers won advantages from chemotherapy added to hormone treatment. [26:10]

Disclosure data for Dr. Lonial and Dr. Henry can also be discovered of their particular person biographies, which might be related to within the paragraphs above. Dr. Grant has no related relationships to divulge.

Was once this podcast helpful? Please subscribe, fee, and assessment Most cancers.Web Podcasts anyplace you pay attention to podcasts. This prerecorded podcast can also be listened to on-line or downloaded on your laptop. A transcript may be to be had. For more info, consult with the Most cancers.Web podcast web page.

Most cancers.Web podcasts are edited for period and content material.

Share Us

Inquiry Now